For Spain’s billionaire Grifols family, which turned a blood-collection business into one of the world’s largest medical ...

Grifols said it plans to outline its strategy as a standalone company after Brookfield Asset Management dropped out of talks ...

The embattled Spanish drugmaker Grifols SA is in talks with banks to refinance about €1.4 billion ($1.48 billion) in bonds ...

The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield ...

La farmacéutica española Grifols SA está en conversaciones con bancos para refinanciar bonos que vencen el próximo año y ...

Canadian investment fund Brookfield said Wednesday it has dropped its bid for Spanish pharmaceutical firm Grifols following ...

The Board of Directors of Grifols (GRFS) announced the termination of discussions with Brookfield Capital Partners UK regarding a ...

In a notice to the Spanish National Securities Market Commission, Grifols (GRFS) stated: “Grifols announces that its Board of Directors held an ...

With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it’s likely back to the ...

The Canadian fund Brookfield has decided to withdraw its interest in a public exclusion offer to acquire Grifols due to ...

The Spanish pharmaceutical company said it considered Brookfield’s offer of 10.50 euros a share undervalued the company and ...

(Bloomberg) -- Grifols SA’s board recommended that shareholders reject Brookfield Asset Management’s indicative offer, which values the Spanish drugmaker at €6.45 billion ($6.8 billion).Most ...